RxSight, Inc. Shares Preliminary Revenue Insights
Today, RxSight, Inc., an innovative company specializing in ophthalmic medical devices, has revealed preliminary financial results for the second quarter of 2025. Focused on enhancing vision quality post-cataract surgery, RxSight continues to adapt to market demands with its flagship Light Adjustable Lens technology. These updates come alongside a conference call scheduled where management will discuss these insights in detail.
Financial Snapshot for Q2 2025
In its preliminary results, RxSight anticipates a revenue of approximately $33.6 million for the second quarter of 2025. This figure marks a 4% decrease compared to the same period last year and an 11% decline from Q1 of this year. The two key components driving this revenue are the sales of Light Adjustable Lenses (LAL®/LAL+®) and Light Delivery Devices (LDD™).
Performance Breakdown
For the second quarter of 2025, RxSight sold about 27,380 Light Adjustable Lenses. While this shows a slight increase of 13% compared to the previous year, it's indicative of a 1% dip in procedure volume against Q1 of this year. Moreover, the company sold only 40 Light Delivery Devices in this quarter, which represents a significant 45% drop compared to Q1 and a 49% decrease from Q2 in the previous year.
Despite these challenges, it’s worth noting that as of June 30, 2025, RxSight has expanded its installed base of Light Delivery Devices to 1,084 units, reflecting a growth of 34% from the previous year.
Revised Financial Guidance for 2025
In light of these preliminary figures, RxSight has adjusted its full-year revenue guidance. The anticipated revenue range for 2025 has been updated to between $120 million to $130 million, down from the earlier expectation of $160 million to $175 million. This adjustment represents an implied decrease of 14% to 7% compared to the last fiscal year.
Gross Margin and Expenses
On a positive note, the company has revised its gross margin guidance upward to a range of 72% to 74%, enhancing their forecast from the previous 71% to 73%. This indicates a likely improvement of 130 to 330 basis points compared to the prior year.
The estimated operating expenses have been adjusted to range from $145 million to $155 million, representing a 7% to 14% increase compared to last year. This figure includes non-cash stock-based compensation anticipated between $27 million to $30 million.
Cash Reserves and Future Reports
RxSight's cash, cash equivalents, and short-term investments as of June 30, 2025, stood at $227.5 million, showing a modest reduction compared to Q1's $229.3 million. This solid cash position assures stakeholders of the company’s operational resilience as they navigate these market conditions.
Upcoming Conference Call
To dive deeper into these results and discuss their implications, RxSight’s management will be hosting a conference call on Tuesday, July 8, 2025, at 5:00 p.m. Eastern Time. Investors can participate by calling the designated numbers and using the specified conference code.
Furthermore, the finalized quarterly financial results are expected to be disclosed in a report set for release on Thursday, August 7, 2025.
About RxSight, Inc.
RxSight, Inc. is at the forefront of the ophthalmic medical device industry, dedicated to enhancing patient outcomes through its innovative technologies. The RxSight Light Adjustable Lens system is unique, offering adjustability even after cataract surgery, which allows for personalized patient care to improve visual outcomes. For further details about RxSight and its products, please visit their official website.
Frequently Asked Questions
What recent financial results did RxSight announce?
RxSight announced preliminary Q2 2025 revenue estimates of approximately $33.6 million, reflecting a decline compared to prior periods.
How has RxSight adjusted its financial guidance for 2025?
The company reduced its full-year revenue guidance from $160-$175 million to a new range of $120-$130 million for 2025.
What improvements did RxSight highlight regarding gross margin?
RxSight has increased its gross margin guidance to 72%-74%, up from the previous range of 71%-73%, indicating enhancing profitability.
When will RxSight report its complete Q2 2025 financial results?
The comprehensive financial results for Q2 2025 are expected to be available on Thursday, August 7, 2025.
How can investors participate in the upcoming conference call?
Investors can join the conference call by dialing the provided numbers and using the conference code on July 8, 2025, at 5:00 p.m. Eastern Time.
